Clario Joins Forces With Mobilise-D to Advance Digital Mobility Outcomes in Clinical Trials
Clario Joins Forces With Mobilise-D to Advance Digital Mobility Outcomes in Clinical Trials
Clario integrates Mobilise-D's algorithms into Clario's Opal wearable sensor system to enable real-world mobility assessments that generate accurate and reliable Digital Mobility Outcomes (DMOs) for enhancing patient outcomes.
Clario将Mobilise-D的算法整合到Clario的Opal可穿戴传感器系统中,以生成准确可靠的数字行动能力(DMOs)进行现实世界的移动性评估,以增强患者的康复效果。
- Clario, a long-standing member of the Mobilise-D consortium, provided essential technology and expertise for the e-clinical outcome assessments (eCOA) data capture during both the technical and clinical validation studies that developed the Mobilise-D algorithms.
- The validated Mobilise-D algorithms integrate into Clario's Opal wearable sensor system, allowing the capture of precise movement measurements in the patients' daily lives to deliver objective, reliable, accurate, and sensitive Digital Mobility Outcomes (DMOs).
- This collaboration enhances clinical outcomes, notably in neuroscience, by pairing reliable digital mobility performance measurements with e-clinical outcome assessments (eCOAs) for a holistic quality-of-life evaluation.
- Clario是Mobilise-D联盟的长期成员,为技术和临床验证研究中的eCOA数据捕获提供了必要的技术和专业知识,为Mobilise-D算法的开发提供了支持。
- 已验证的Mobilise-D算法集成到Clario的Opal可穿戴传感器系统中,允许捕捉患者日常生活中的精确的运动测量数据,以提供客观、可靠、准确、敏感的数字行动能力(DMOs)。
- 此项合作通过为数字行动能力(DMOs)捕获数据的e-clinical outcome assessments(eCOAs)与可靠的数字行动性能测量相结合,使临床效果得到增强,特别是在神经科学方面。
PHILADELPHIA, Aug. 13, 2024 /PRNewswire/ -- Clario, a leading provider of technologies and endpoint data solutions for clinical trials, today announced the enhancement of its digital capture of patient mobility data through the Mobilise-D consortium partnership. This collaboration integrates the recently validated Mobilise-D Digital Mobility Outcomes (DMOs) with Clario's Opal wearable sensor system, allowing clinicians to measure the way patients move in their daily life versus a single timepoint when they visit a clinic. DMOs deliver multiple advantages over conventional clinical scales when capturing information about human movement — they are more objective, reliable, accurate, and sensitive.
2024年8月13日,美国费城/PRNewswire/-- Clario是临床试验技术和终点数据解决方案的领先提供商,今天宣布通过Mobilise-D联盟合作伙伴关系提高了其对患者移动数据的数字捕获。此次合作将最新验证的Mobilise-D数字行动能力(DMOs)与Clario的Opal可穿戴传感器系统相结合,使临床医生能够测量患者日常生活中的运动方式而不是在就诊时一次性测量,与传统的临床评分相比,DMOs在捕捉有关人类运动的信息时具有多重优势,更客观、可靠、准确、敏感。
As a member of the Mobilise-D consortium, Clario provided essential technology and expertise for the e-clinical outcome assessments (eCOA) data capture, during both the technical and clinical validation studies that developed the algorithms. Leveraging this experience, Clario offers advanced solutions that integrate the validated Mobilise-D algorithms with its wearable sensors to assess mobility performance and deliver DMOs.
作为Mobilise-D联盟的成员,Clario为技术和临床验证研究中的eCOA数据捕获提供了必要的技术和专业知识,利用这方面的经验,Clario提供了与其可穿戴传感器相集成的先进解决方案来评估运动表现并交付数字行动能力(DMOs)。
"It has been a privilege to contribute to the Mobilise-D consortium and advance digital mobility data for use in clinical trials," said Kristen Sowalsky, Ph.D., D.C., VP, Product Management and Scientific Affairs, Precision Motion at Clario. "These developments are integral for demonstrating real-world patient outcomes, particularly in neuroscience where mobility insights outside of clinical settings are essential to assess treatment efficacy and quality-of-life."
Clario的Precision Motion副总裁、产品管理和科学事务博士Kristen Sowalsky表示:“能为Mobilise-D联盟做出贡献并推动数字移动数据在临床试验中的应用是一种荣幸。这些进展对于展示现实世界的患者康复效果尤为重要,尤其是在神经科学领域,移动性洞见对于在临床环境外评估治疗疗效和生活质量至关重要。”
Clario is implementing these algorithms in a study with multiple sclerosis (MS) patients to establish the technical equivalence of its Precision Motion wearable device, Opal. In addition, Clario can provide the mobility performance data from wearable sensors along with e-clinical outcome assessments (eCOA), enhancing clinical outcomes. This, alongside Clario's offerings in medical imaging, cardiac, and respiratory endpoints, meets a broad scope of clinical trial solutions addressing diverse needs.
Clario正在一项多发性硬化(MS)患者的研究中实施这些算法,以建立其Precision Motion可穿戴设备Opal的技术等价性。此外,Clario可以提供可穿戴传感器测量的移动性能数据以及eCOA,从而增强临床结果。结合Clario在医学成像、心脏和呼吸终点的提供,涵盖了各种临床试验解决方案,满足了不同的需求。
Lynn Rochester, Ph.D., Professor of Human Movement Science at the Translational and Clinical Research Institute, Newcastle University in the United Kingdom co-led the Mobilise-D consortium. On the Clario partnership, Dr. Rochester said, "Working with Clario has been instrumental in our clinical studies to validate our DMO algorithms and ensuring their quality in clinical settings. Their expertise in data capture and analysis will contribute significantly to the success of our work, and we are excited about the future applications of this technology."
英国纽卡斯尔大学Translational and Clinical Research Institute人类运动科学教授Lynn Rochester博士共同领导了Mobilise-D联盟。关于与Clario的合作,Rochester博士表示:“与Clario合作对于我们验证DMO算法和确保其在临床环境中的质量至关重要。他们在数据捕获和分析方面的专业知识将对我们的工作的成功产生重要贡献,我们对该技术未来的应用充满期待。”
To learn more about Clario and its wearable sensor technologies, please visit Clario.com.
要了解有关Clario及其可穿戴传感器技术的更多信息,请访问Clario.com。
About Clario
关于Clario
Clario is a leading healthcare research and technology company that generates high quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
Clario是一家领先的医疗健康研究和技术公司,为我们的制药、生物技术和医疗设备合作伙伴生成高质量的临床证据。我们提供综合的证据生成解决方案,结合了eCOA、心脏解决方案、医学影像、精密运动和呼吸终点。
Since our founding more than 50 years ago, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported clinical trials over 26,000 times in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2019.
自50多年前创立以来,Clario为改变世界生活提供了深厚的科学专业知识和广泛的终点技术。我们的终点数据解决方案已经支持了超过26,000次的临床试验,在100多个国家使用。我们全球的科学、技术和运营专家支持了自2019年以来60%以上的FDA药物审批。
For more information, go to Clario.com or follow us on LinkedIn.
有关更多信息,请访问Clario.com或关注我们的LinkedIn。
About IMI Mobilise-D
关于IMI Mobilise-D
Mobilise-D () is a consortium funded under the EU Innovative Medicines Initiative comprised of experts from 22 academic institutions, 12 industry partners from pharmaceutical, technology, and clinical research organisations, and people with diverse health conditions and mobility impairments. The primary objective of Mobilise-D was to develop a novel method to accurately and reliability assess change in one's mobility in the real-world environment using digital technologies, including a single body worn device. The project focused on conditions which affect mobility, including chronic obstructive pulmonary disease, Parkinson's disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. It has delivered a systematic approach to real-world mobility assessment that is standardised, validated and free. The Mobilise-D results will help to improve accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.
Mobilise-D (http://www.mobilise-d.eu/)是一个由来自22个学术机构、12个制药、技术和临床研究组织的行业合作伙伴以及健康状况和行动能力多样的人组成的欧盟创新药物倡议联盟。 Mobilise-D最主要的目标是利用数字技术(包括单一的穿戴式设备)开发一种新的方法,准确可靠地评估现实世界环境下的行动能力变化。该项目关注影响行动能力的状况,包括慢性阻塞性肺疾病、帕金森病、多发性硬化症、髋部骨折康复和充血性心力衰竭等。Mobilise-D提供了一种经过系统标准化、验证并且免费的现实世界移动性评估方法。Mobilise-D的结果将有助于改进临床试验和患者治疗中对日常生活行动能力的准确评估,从而为改善和更个性化的护理做出贡献。
Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]
媒体联系人:
David Malley
品牌、内容策略和通信总监David Malley
[email protected]
SOURCE Clario
来源:Clario